Actuated Medical Expands Expertise in Forensic DNA Analysis with Acquisition of Mitotyping Technologies LLC
Actuated Medical Expands Expertise in Forensic DNA Analysis with Acquisition of Mitotyping Technologies LLC
BELLEFONTE, PA, December 5, 2023 — Actuated Medical, a leading innovator in medical device technologies, announced today the successful acquisition of Mitotyping Technologies LLC, a prominent DNA forensic company specializing in advanced mitochondrial DNA analysis. This strategic move reflects Actuated Medical’s commitment to diversification and growth, expanding its capabilities into the field of forensic science.
Mitotyping Technologies LLC has established itself as a trailblazer in the DNA forensic industry, providing cutting-edge solutions for mitochondrial DNA analysis for over 24 years. The acquisition aligns with Actuated Medical’s vision to explore new avenues of innovation and leverage its expertise in precision engineering for applications beyond the medical field.
“We are excited to welcome Mitotyping Technologies into the Actuated Medical family,” said Maureen L. Mulvihill, CEO and Founder of Actuated Medical. “This strategic acquisition not only strengthens our portfolio but also positions us at the forefront of forensic mitochondrial DNA analysis. Mitotyping Technologies has a stellar reputation for delivering high-quality results, and we look forward to integrating their expertise into our broader mission of advancing science and technology.”
Mitotyping Technologies is known for its team of highly skilled scientists and exceptional success rate when working with minute, aged, and highly degraded samples. Using a unique, customized casework approach, Mitotyping Technologies has been instrumental in numerous forensic investigations. This acquisition enables Actuated Medical to leverage Mitotyping Technologies’ extensive experience and established relationships within the forensic community.
“We are thrilled to join forces with Actuated Medical, a company known for its commitment to excellence and innovation,” said Gloria Dimick, Technical Leader and Forensic Examiner at Mitotyping Technologies. “Together, we believe we can push the boundaries of forensic mitochondrial DNA analysis, driving advancements that will have a positive impact on the field and contribute to the resolution of complex cases.”
The integration of Mitotyping Technologies into Actuated Medical’s portfolio enhances the company’s ability to address the growing demand for advanced forensic DNA solutions. The combined resources, knowledge, and technologies will empower Actuated Medical to make significant contributions to the field of forensic science.
About Mitotyping Technologies LLC:
Mitotyping Technologies, based in the vibrant State College area, shattered the myth surrounding the legendary Wild Bill Longley with an exuberant triumph. While Texas folklore hinted at his elusive escape from the hangman’s noose three times, Mitotyping Technologies definitively debunked the tale, proving his identity through forensic Mitochondrial DNA analysis. As a global leader in this field for over 20 years, their accredited DNA forensic laboratory has been instrumental in active criminal cases, post-conviction exonerations, cold cases, maternal relatedness, and missing persons investigations. Their unparalleled expertise extends to achieving superior recovery rates for mitochondrial DNA even in the most challenging samples. Mitotyping Technologies doesn’t just solve cases; they redefine what’s possible in forensic science with unmatched enthusiasm and dedication.
Get Updates
from LSPA
Stay up-to-date on the latest news and events from Life Sciences PA, insights from the life sciences industry, and so much more!
Life Sciences Pennsylvania was founded in 1989 by a biotech scientist at Penn State University. Today it has grown to represent the entire life sciences industry – medical device companies, pharmaceutical companies, investment organizations, research institutions, and myriad service industries that support the life sciences in Pennsylvania.